Neurion Pharmaceuticals Wins $500,000 NIMH SBIR Grant

Neurion Pharmaceuticals, an ion channel drug discovery company, announced that it has been awarded a $500,000 Phase I SBIR (Small Business Innovation Research) grant, administered by the NIMH (National Institute of Mental Health). Neurion is using the grant to support its ongoing development of safer and more effective drugs to treat anxiety.

()a href="http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050602005092&newsLang=en" target="_blank">Business Wire